(Q37425218)

20 August 2017

1 reference

title

The reformulation of amphotericin B for oral administration to treat systemic fungal infections and visceral leishmaniasis (English)

1 reference

20 August 2017

main subject

visceral leishmaniasis

1 reference

1 reference

2

Kishor M Wasan

1 reference

20 August 2017

Sheila J Thornton

1

1 reference

20 August 2017

language of work or name

English

0 references

publication date

1 March 2009

1 reference

Expert Opinion on Drug Delivery

20 August 2017

published in

1 reference

20 August 2017

volume

6

1 reference

20 August 2017

issue

3

1 reference

20 August 2017

page(s)

271-284

1 reference

Changing patterns and trends in systemic fungal infections

20 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F17425240902802861

Treatment options for visceral leishmaniasis: a systematic review of clinical studies done in India, 1980-2004

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240902802861

Comparison of three treatment regimens with liposomal amphotericin B (AmBisome) for visceral leishmaniasis in India: a randomized dose-finding study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240902802861

A comparative evaluation of amphotericin B and sodium antimony gluconate, as first-line drugs in the treatment of Indian visceral leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240902802861

How do the polyene macrolide antibiotics affect the cellular membrane properties?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240902802861

The Discovery and Development of Amphotericin B

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240902802861

Visceral leishmaniasis: what are the needs for diagnosis, treatment and control?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240902802861

The immunology of susceptibility and resistance to Leishmania major in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240902802861

Phlebotomine sand flies and Leishmania parasites: friends or foes?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240902802861

Transmission of Leishmania metacyclic promastigotes by phlebotomine sand flies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240902802861

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240902802861

Visceral leishmaniasis: current status of control, diagnosis, and treatment, and a proposed research and development agenda

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240902802861

Leishmaniasis treatment--a challenge that remains: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240902802861

Molecular mechanisms of antimony resistance in Leishmania

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240902802861

Effect of heat-treatment and the role of phospholipases on Fungizone-induced cytotoxicity within human kidney proximal tubular (HK-2) cells and Aspergillus fumigatus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240902802861

New treatment approach in Indian visceral leishmaniasis: single-dose liposomal amphotericin B followed by short-course oral miltefosine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240902802861

Injectable paromomycin for Visceral leishmaniasis in India

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240902802861

The activity of alkyl phosphorylcholines and related derivatives against Leishmania donovani

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240902802861

The activities of four anticancer alkyllysophospholipids against Leishmania donovani, Trypanosoma cruzi and Trypanosoma brucei

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240902802861

Treatment of leishmaniasis with miltefosine: 2008 status

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240902802861

Mechanisms of experimental resistance of Leishmania to miltefosine: Implications for clinical use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240902802861

Characterisation of Leishmania donovani promastigotes resistant to hexadecylphosphocholine (miltefosine).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240902802861

Spread of vector-borne diseases and neglect of Leishmaniasis, Europe

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240902802861

Selection and phenotype characterisation of sitamaquine-resistant promastigotes of Leishmania donovani

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240902802861

Aspergillus to Zygomycetes: causes, risk factors, prevention, and treatment of invasive fungal infections.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240902802861

21 January 2018

Azole Antifungal Agents

1 reference

https://api.crossref.org/works/10.1517%2F17425240902802861

In vitro susceptibility and synergy studies of Aspergillus species to conventional and new agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240902802861

Newer systemic antifungal agents : pharmacokinetics, safety and efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240902802861

New formulations and derivatives of amphotericin B for treatment of leishmaniasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240902802861

Formulation of amphotericin B as nanosuspension for oral administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240902802861

Cochleates. Lipid-based vehicles for gene delivery-concept, achievements and future development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240902802861

Antifungal activity of amphotericin B cochleates against Candida albicans infection in a mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240902802861

Efficacy of oral cochleate-amphotericin B in a mouse model of systemic candidiasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240902802861

Efficacy of orally delivered cochleates containing amphotericin B in a murine model of aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240902802861

Enhancing drug absorption using lipids: a case study presenting the development and pharmacological evaluation of a novel lipid-based oral amphotericin B formulation for the treatment of systemic fungal infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240902802861

Phospholipases and phagocytosis: the role of phospholipid-derived second messengers in phagocytosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240902802861

Drug repositioning: identifying and developing new uses for existing drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240902802861

Impact of lipoproteins on the biological activity and disposition of hydrophobic drugs: implications for drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240902802861

10.1517/17425240902802861

21 January 2018

Identifiers

DOI

1 reference

20 August 2017

1 reference